Recursion Announced The Full Enrollment Of Its Phase 2 SYCAMORE Trial Evaluating REC-994 For Cerebral Cavernous Malformation, Abnormally Formed Blood Vessels In The Brain Or Spinal Cord That Can Alter Blood Flow
Portfolio Pulse from Benzinga Newsdesk
Recursion Pharmaceuticals has announced the full enrollment of its Phase 2 SYCAMORE trial, which evaluates REC-994 for the treatment of cerebral cavernous malformation (CCM), a condition involving abnormally formed blood vessels in the brain or spinal cord.
June 13, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Recursion Pharmaceuticals' full enrollment of its Phase 2 SYCAMORE trial for REC-994 may positively impact the company's stock price in the short term.
The full enrollment of the Phase 2 SYCAMORE trial indicates progress in the development of REC-994 for CCM treatment. This news may be seen as a positive milestone for Recursion Pharmaceuticals, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100